Sandra Casimiro

List of Publications by Year
in descending order

28	853	566801 15	642321 23
papers	citations	h-index	g-index

28	28	28	1502
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The critical role of the bone microenvironment in cancer metastases. Molecular and Cellular Endocrinology, 2009, 310, 71-81.	1.6	128
2	Targeting bone metastases in prostate cancer: improving clinical outcome. Nature Reviews Urology, 2015, 12, 340-356.	1.9	87
3	Bone metastasis risk factors in breast cancer. Ecancermedicalscience, 2017, 11, 715.	0.6	79
4	Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer. Clinical Colorectal Cancer, 2016, 15, 170-178.e3.	1.0	70
5	RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro. PLoS ONE, 2013, 8, e63153.	1.1	66
6	MTA1 Promotes STAT3 Transcription and Pulmonary Metastasis in Breast Cancer. Cancer Research, 2013, 73, 3761-3770.	0.4	61
7	Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis. Cancer and Metastasis Reviews, 2020, 39, 603-623.	2.7	50
8	Bone remodeling markers and bone metastases: From cancer research to clinical implications. BoneKEy Reports, 2015, 4, 668.	2.7	45
9	Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors. Clinical and Experimental Metastasis, 2012, 29, 155-164.	1.7	41
10	Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?. International Journal of Molecular Sciences, 2016, 17, 1415.	1.8	35
11	The Roadmap of RANKL/RANK Pathway in Cancer. Cells, 2021, 10, 1978.	1.8	29
12	^{99m}Tc-Tricarbonyl Complexes Functionalized with Anthracenyl Fragments: Synthesis, Characterization, and Evaluation of Their Radiotoxic Effects in Murine Melanoma Cells. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 551-563.	0.7	24
13	Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancerâ€induced bone loss. British Journal of Clinical Pharmacology, 2019, 85, 1114-1124.	1.1	21
14	Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. International Journal of Molecular Sciences, 2019, 20, 695.	1.8	18
15	N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases. Oncologist, 2016, 21, 1418-1426.	1.9	17
16	Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer. Oncotarget, 2020, 11, 1714-1728.	0.8	15
17	Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs. OncoTargets and Therapy, 2012, 5, 409.	1.0	14
18	Biological assessment of novel bisphosphonate-containing 99mTc/Re-organometallic complexes. Journal of Organometallic Chemistry, 2014, 760, 197-204.	0.8	14

#	Article	IF	Citations
19	c-Met expression in renal cell carcinoma with bone metastases. Journal of Bone Oncology, 2020, 25, 100315.	1.0	10
20	Identification of pathogenesis-related ESTs in the crucifer downy mildew oomycete Hyaloperonospora parasitica by high-throughput differential display analysis of distinct phenotypic interactions with Brassica oleracea. Journal of Microbiological Methods, 2006, 66, 466-478.	0.7	8
21	The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases. Oncotarget, 0, 7, 41380-41389.	0.8	7
22	Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases. Cancers, 2020, 12, 2034.	1.7	5
23	Lupin Protein Concentrate as a Novel Functional Food Additive That Can Reduce Colitis-Induced Inflammation and Oxidative Stress. Nutrients, 2022, 14, 2102.	1.7	4
24	A Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases. Cancers, 2022, 14, 893.	1.7	2
25	Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 0, , 337-361.	0.5	2
26	Dynamic modeling of bone remodeling, osteolytic metastasis and PK/PD therapy: introducing variable order derivatives as a simplification technique. Journal of Mathematical Biology, 2021, 83, 39.	0.8	1
27	Zoledronic Acid: Its Use in the Treatment of Breast Cancer. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S2353.	0.4	0
28	N-telopeptide of type I collagen (NTX) dynamics over one year of determinations in patients with breast cancer (BC) with bone metastases (BM): Predictive factors of outcome.. Journal of Clinical Oncology, 2013, 31, 9634-9634.	0.8	0